TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/14/2026
Back to search
Official data from USPTO
BAUSCH HEALTH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
87
Latest update
05/16/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
06/08/2018
Registration date
12/21/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/21/2021
Last transaction
05/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/12/2014
First use in commerce
03/12/2014
Drawing code
3
Owner type
03
Owner location
Rochester, NY, US
Examiner
DELGIZZI, RONALD ERNEST
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "BAUSCH" in gray. The "H" in "BAUSCH" has an extended horizontal center forming a cross in which in the center of the cross is a blue square. The word "HEALTH" follows "BAUSCH" and appears in blue and lowercase, except the first letter "H". The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark.
Holders and representatives
Holders
Bausch & Lomb Incorporated
Representatives
Robert J. Gorman Bausch + Lomb
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsan oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;diazepam rectal gel; Pharmaceutical preparations for the treatment of cancerneurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravisdepressionmood/anxiety conditionssolar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the preventiontreatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the preventiontreatment and alleviation of epilepsy; pharmaceutical preparations and substances for the preventiontreatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the preventiontreatment and alleviation of cardio-pulmonary disordersdiseasesconditionsailments; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditionsailments of the circulatory system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of hypertensionhigh blood pressureheart failure and ventricular dysfunction; pharmaceutical preparations and substances for the preventiontreatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the preventiontreatment and alleviation of central nervous system disordersdiseasesconditions and ailmentscentral nervous system movement disordersocular motility disordersspinal cord diseasesencephalitiscerebral palsyinsomniamood disordersbipolar disorderseizure disorders; pharmaceutical preparations and substancesfibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the respiratory system; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseasesauto immune motility diseasesimmunologic deficiency syndromesauto immune diseasesAcquired Immune Deficiency Syndrome (AIDS)hypersensitivityallergiestumors of the immunological organs; pharmaceutical preparations and substances for the preventiontreatment and alleviation of disordersdiseasesconditions and ailments of the musculoskeletal systembone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; antiviral pharmaceutical compounds; antiobesity agent in the nature of a pharmaceutical preparation; Dermotherapeutic preparation for use in the treatment of obesity; Pharmaceutical productslipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; Pharmaceutical preparationsa topical cream for the treatment of pre-cancerous skin lesions; pharmaceutical preparations and substances for the prevention and treatment of disordersdiseasesconditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nauseaemesis; Medicines and medicinal preparations for human purposesto support treatment of hemorrhoidschronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoidschronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoidschronic venous insufficiency and lymphedema; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical preparations and substances for the treatment of epilepsyseizures and neurological and psychological diseases and disorders; pharmaceutical preparations and substances for the preventiontreatment and alleviation of stress; pharmaceutical preparations and substances for the preventiontreatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the preventiontreatment and alleviation of hypertension; pharmaceutical preparations and substances for the preventiontreatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the preventiontreatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the preventiontreatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the preventiontreatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the preventiontreatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substancesfibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the preventiontreatment and alleviation of pain and inflammationanti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the preventiontreatment and alleviation of migraines; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparationsimmunomodulators; anticholinesterase preparation for the preventiontreatment and alleviation of a neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the preventiontreatment and alleviation of anxietydepressiondepressive disorders and mental illness
Publications
History of USPTO decisions and trademark events.
87 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/14/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/14/2026
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
09/10/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/25/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
10/11/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/28/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/21/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
12/14/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/10/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
06/23/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
05/25/2022
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
03/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
12/21/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/19/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/18/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/10/2021
IUAF
USE AMENDMENT FILED
11/07/2021
EISU
TEAS STATEMENT OF USE RECEIVED
11/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/16/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/16/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/16/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/10/2021
EX5G
SOU EXTENSION 5 GRANTED
09/09/2021
EXT5
SOU EXTENSION 5 FILED
09/05/2021
EEXT
SOU TEAS EXTENSION RECEIVED
09/05/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/23/2021
EX4G
SOU EXTENSION 4 GRANTED
03/21/2021
EXT4
SOU EXTENSION 4 FILED
03/21/2021
EEXT
SOU TEAS EXTENSION RECEIVED
03/21/2021
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
11/25/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/29/2020
EX3G
SOU EXTENSION 3 GRANTED
09/25/2020
EXT3
SOU EXTENSION 3 FILED
09/25/2020
EEXT
SOU TEAS EXTENSION RECEIVED
09/25/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/11/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/11/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/11/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/11/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/11/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/28/2020
EX2G
SOU EXTENSION 2 GRANTED
03/26/2020
EXT2
SOU EXTENSION 2 FILED
03/26/2020
EEXT
SOU TEAS EXTENSION RECEIVED
03/26/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/30/2019
EX1G
SOU EXTENSION 1 GRANTED
10/29/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/29/2019
NREV
NOTICE OF REVIVAL - E-MAILED
09/30/2019
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
09/27/2019
PETG
PETITION TO REVIVE-GRANTED
09/27/2019
PROA
TEAS PETITION TO REVIVE RECEIVED
09/27/2019
EXT1
SOU EXTENSION 1 FILED
09/26/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/26/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/29/2019
PUBO
PUBLISHED FOR OPPOSITION
01/29/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/22/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/20/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/20/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/19/2018
GNRT
NON-FINAL ACTION E-MAILED
12/19/2018
CNRT
NON-FINAL ACTION WRITTEN
12/19/2018
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
12/11/2018
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
11/20/2018
ALIE
ASSIGNED TO LIE
11/02/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/22/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/22/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/22/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/22/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/04/2018
GNRT
NON-FINAL ACTION E-MAILED
10/04/2018
CNRT
NON-FINAL ACTION WRITTEN
10/04/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/22/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/22/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/15/2018
GNRT
NON-FINAL ACTION E-MAILED
08/15/2018
CNRT
NON-FINAL ACTION WRITTEN
08/15/2018
DOCK
ASSIGNED TO EXAMINER
08/15/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/15/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/14/2018
NWAP
NEW APPLICATION ENTERED
06/12/2018
Continuous trademark protection
Get notified about every new filing that threatens BAUSCH HEALTH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.